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Sex Med 2The International Diabetes Federation estimates that approximately 0.4% of the Belgian population is diagnosed with
type 1 diabetes mellitus, which is similar to other industrialized countries. The prevalence of transgenderism is esti-
mated at 0.6% to 0.7% of all adults in Western populations. In this study, we evaluated whether there was an increased
prevalence of type 1 diabetes mellitus in transgender people in the local cohort. Medical records of transgender patients
were analyzed retrospectively. From January 1, 2007 until October 10, 2016, 1,081 transgender patients presented at a
tertiary reference center to start hormonal treatment. Nine of these 1,081 patients were previously diagnosed with type
1 diabetes mellitus and 1 was diagnosed with latent autoimmune diabetes in adults. A 2.3-fold higher prevalence of type
1 diabetes mellitus was observed in transgender patients. We concluded that type 1 diabetes mellitus was more
prevalent in transgender patients than one would expect from population prevalences. This could be a spurious result in
a local cohort, because a causal relation seems unlikely, but our ﬁnding might encourage other centers to investigate this
putative association. Defreyne J, De Bacquer D, Shadid S, et al. Is Type 1 Diabetes Mellitus More Prevalent Than
Expected in Transgender Persons? A Local Observation. Sex Med 2017;5:e215ee218.
Copyright  2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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At the Ghent University Hospital outpatient endocrine clinic
(Ghent, Belgium), recognized as a tertiary referral center for
transgender care, we perceived a relatively high prevalence of type
1 diabetes mellitus in transgender individuals seeking gender-
afﬁrming hormonal treatment. However, there is no known
association between type 1 diabetes mellitus and transgenderism.
In Belgium, the prevalence of type 1 diabetes mellitus in the
Belgian population is estimated at 0.4% by the International
Diabetes Federation (IDF), which is similar to the prevalence
rate of type 1 diabetes mellitus in the Netherlands (0.48%).1
Exact incidence rates are unknown, because newly diagnosed
cases are not systematically documented in Belgium.arch 13, 2017. Accepted June 5, 2017.
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017;5:e215ee218Previous studies on the prevalence of transgenderism reported
mainly on the prevalence of transgender persons looking for
gender-afﬁrming care, which led to an underestimation of the
prevalence of transgenderism.2 In a recent study by Van
Caenegem et al,2 the overall prevalence of transgenderism in
Flanders, Belgium was estimated at 0.6% to 0.7% of all adults.
Theoretically, the options for gender afﬁrmation include
social, psychological, hormonal, and surgical transitioning,
although decisions regarding gender-afﬁrmative therapy should
be made for the individual. Options for gender-afﬁrming hor-
monal treatment include testosterone administration (intramus-
cular injections or gel applications) in transmen and estrogens
(orally or transdermally administrated) and antiandrogens in
transwomen.
Given the relatively low prevalence of transgenderism and type
1 diabetes mellitus, combined prevalence in one person is
expected to be rare. Therefore, we evaluated whether the number
of transgender persons with the comorbidity of type 1 diabetes
mellitus was higher than expected in our center.METHODS
To evaluate a possible association between type 1 diabetes
mellitus and transgenderism in our local cohort, medicale215
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e216 Defreyne et alrecords of transgender persons were analyzed retrospectively.
To investigate whether the difference between expected and
observed numbers of transgender persons presenting with type
1 diabetes mellitus was signiﬁcant, a c2 statistical test
([observed  expected]2/expected) was performed using IDF
estimates.yp
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.RESULTS
From January 1, 2007 until October 10, 2016, 1,081 trans-
gender persons and 372 patients with type 1 diabetes mellitus
presented at the endocrinology department of our hospital. We
found that 9 of 1,081 transgender persons were previously
diagnosed with type 1 diabetes mellitus and 1 person was pre-
viously diagnosed with latent autoimmune diabetes of adult-
hood, a form of type 1 diabetes mellitus that develops later in
adulthood (Table 1). Of these transgender individuals, eight
(80%) were transwomen (male-to-female transgender persons)
and two (20%) were transmen (female-to-male transgender
persons). Their mean age was 36.7 years (range ¼ 19e53 years)
and mean age at diagnosis of type 1 diabetes mellitus was 15.7
years (range ¼ 3e29 years). Five transgender persons recalled
their ﬁrst feelings of gender incongruence at a mean age of 6.8
years (range ¼ 4e13 years). For two persons, this information
was not found in the medical records, one did not recall, and two
persons responded that they felt this way since “early childhood.”
The reported trans-persons started gender-afﬁrming hormonal
therapy at mean age of 29.4 years (range ¼ 19e50 years). The
expected number of persons previously diagnosed with type 1
diabetes mellitus presenting for transgender care was 4.32
(1,081  0.4%). The calculated c2 statistic of 7.47 (P ¼ .006)
indicated that the higher prevalence of type 1 diabetes mellitus in
transgender individuals (0.92%) was highly signiﬁcant (2.3 times
higher; Figure 1).Ta
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.DISCUSSION
We found an increased number of transgender persons with
type 1 diabetes mellitus at our center compared with the
expectation based on the combined prevalence of transgenderism
and type 1 diabetes mellitus in Western populations. Because not
all transgender persons wish or search for gender-afﬁrming hor-
monal treatment, this number could be an understimation.2
The predominant effector mechanism of type 1 diabetes
mellitus is autoimmunity, although the primary cause is
unknown.3 There are case reports describing other autoimmune
diseases in transgender persons, although those researchers
correlated their observations with the administered hormonal
therapy, whereas in our patients type 1 diabetes mellitus was
already prevalent before initiation of hormonal therapy.4,5
A possible pathophysiologic mechanism behind the observed
correlation between type 1 diabetes mellitus and transgenderism
is difﬁcult to fathom, if only because the etiology of trans-
genderism remains unclear. Etiologic theories include atypicalSex Med 2017;5:e215ee218
Figure 1. Venn diagram of the transgender population with type 1
diabetes mellitus (January 1, 2007 through October 10, 2016) at
Ghent University Hospital.
Prevalence of Type 1 Diabetes Mellitus in Transgender Persons e217gender development during childhood and parental and familial,
genetic, and biological factors.6 Because the incidence of type 1
diabetes mellitus is known to peak during puberty,3 a time when
serum sex hormone levels increase, one could hypothesize a
correlation between the administration of cross-sex hormones in
transgender persons and the occurrence of type 1 diabetes
mellitus. However, the trans-persons in our study cohort had
known type 1 diabetes mellitus before they initiated cross-sex
hormone therapy. So far, no studies have shown autoimmunity
to be a cause for gender dysphoria.
Another possible explanation for the correlation between type
1 diabetes mellitus and gender dysphoria might be that the
prolonged psychological stress of the gender dysphoria—mostly
present at a young age in our cohort—is a precipitating factor
for type 1 diabetes mellitus. Several studies have provided
evidence for an association between psychological stress and
type 1 diabetes mellitus.7e13 Many transgender persons expe-
rience mental health issues and chronic stress (often called
“minority stress”) owing to internalized stigma, victimization,
social rejection, and lack of social support.14e16 This chronic
psychoneurotic distress decreases markedly after the initiation of
gender-afﬁrming hormonal therapy.17e19 Emotional problems
such as depression and anxiety are frequently reported in
trans-children and trans-adolescents,20 with ostracism and peer
victimization as risk factors accounting for co-occurring general
psychopathology in gender non-conforming children and
adolescents.21
Different types of stress are known to cause excessive release of
stress hormones (cortisol, catecholamines), which can increase
insulin requirements and increase stress on pancreatic b-cells.
Another hypothesis is that stress accelerates the autoimmune
destruction of pancreatic b-cells by affecting the immune
system.22
To date, to our knowledge, there is no literature on the
management of type 1 diabetes mellitus in transgender patients.
We recommend transgender patients seek care for their type 1
diabetes mellitus in a center where health care providers treat
transgender persons with respect and dignity, independent of
their personal views of gender incongruence.Sex Med 2017;5:e215ee218As for the strengths and weaknesses of this study, there might
be a selection bias. The reported transgender persons visited a
diabetologist close to their home for the management of type 1
diabetes mellitus. None of them were treated for type 1 diabetes
mellitus in our hospital. However, the fact that a trans-person is
seen by a peripheral endocrinologist for follow-up of type 1
diabetes mellitus can increase the possibility that this person
would be referred to an endocrinologist specialized in trans-
gender care.CONCLUSIONS
Type 1 diabetes mellitus seemed more prevalent in trans-
gender patients visiting a tertiary endocrinology center than one
would expect from population prevalence. This could be a
spurious result in a local cohort, because a causal relation seems
unlikely and a pathophysiologic mechanism is difﬁcult to
fathom, but our ﬁndings might encourage other centers to
investigate this association in larger cohorts.
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